Access cutting-edge multiple myeloma treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access multiple myeloma specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related multiple myeloma treatment provided free
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread
Sponsor: ECOG-ACRIN Cancer Research Group
Check if you qualify for this multiple myeloma clinical trial in Phoenix, AZ
If you're searching for multiple myeloma treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced multiple myeloma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.